{"success":true,"data":{"pressRelease":{"id":"167413","rtpr_id":"nBw4KfFrDa-20261013","ticker":"A","exchange":"NYSE","all_tickers":["A"],"title":"Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence","author":"Business Wire","published_at":"2026-10-13T12:00:00.446Z","article_body":"Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and\nScientific Intelligence\n\nAdvances Agilent’s position as a leading pathology solutions provider, with\na unique and differentiated combination of instruments, reagents, and software\n\nAcquisition seamlessly builds on Agilent’s pathology portfolio expansion\nefforts and widens strategic moat in high-growth market\n\nAgilent Technologies Inc. (NYSE: A) today announced it has entered into a\ndefinitive agreement to acquire Proscia®, a provider of digital pathology\nsoftware for clinical and life-sciences customers, in an all-cash transaction\nvalued at $240 million in cash at closing and up to an additional $30 million\nbased on achieving future performance milestones.\n\nProscia is a leading independent provider of enterprise digital pathology\nsoftware, serving as a key enabler to address emerging trends in the $5\nbillion Pathology market. Proscia’s software platform serves as a central\noperating layer for digital pathology, supporting clinical and life-sciences\ncustomers across the U.S. and Europe. By connecting slide scanners, laboratory\ninformation systems, image-analysis applications, AI tools, people, and data,\nProscia’s innovative technology enables customers to manage images, data,\nand workflows in one unified environment. Proscia serves more than 4,000\nlaboratories, hospitals, and clinics today as well as 16 of the top 20\npharmaceutical companies, with trailing twelve months revenue exceeding $18\nmillion. Proscia was named 2026 Best in KLAS for Digital Pathology and earned\nthe highest performance score across both U.S. and European markets.\n\nAgilent and Proscia entered into a multi-year distribution agreement in\nSeptember 2022 to offer a comprehensive digital diagnostic-pathology system.\nToday’s announcement builds on Agilent’s established pathology solutions\nand its partnership with Proscia.\n\n“Digital pathology is quickly becoming the foundation for pathology data\ngeneration, analysis, and application across biopharmaceutical research,\nclinical development, and diagnostics, and our acquisition of Proscia\nmeaningfully expands our presence in this fast-growing market,” said Agilent\nPresident and CEO Padraig McDonnell. “The acquisition establishes an Agilent\nplatform for scientific intelligence in tissue-based precision medicine,\nconnecting data generation with AI-based interpretation in a workflow that\nsupports biomarker research through routine clinical use. With Proscia’s\nleading platform and talented team, we will be better equipped to help\nlaboratories and biopharma customers manage and derive insights from pathology\ndata. We look forward to welcoming the Proscia team to Agilent and working\ntogether to accelerate adoption of AI-enabled pathology workflows to advance\ndrug discovery and companion-diagnostics solutions and create long-term value\nfor customers and shareholders.”\n\n“This agreement with Agilent marks an exciting milestone for Proscia and\nreflects the strength of the platform our team has built,” said David West,\nCo-Founder and CEO of Proscia. “Agilent shares our vision for advancing\npathology through open, digital, and AI-enabled solutions. Together, we can\naccelerate innovation while continuing to provide customers with the\nflexibility they need across clinical and life-sciences workflows. I am\ngrateful to the entire Proscia team, whose dedication made this milestone\npossible, and look forward to building on our work as part of Agilent.”\n\nStrategic and Financial Benefits of the Acquisition\n\nThe combination builds on the successful completion of Agilent’s recent\ntransaction with Biocare Medical, and offers meaningful strategic and\nfinancial benefits, including:\n\n\n * Strengthens Pathology Portfolio with a Leading Digital Pathology Platform.\nThis acquisition strengthens Agilent's existing leadership in pathology\ninstrumentation and reagents, combining industry-leading diagnostic\ncapabilities with Proscia's vendor-agnostic digital pathology platform and\nestablished customer base. Proscia’s platform holds FDA 510(k) clearance for\nprimary diagnosis. The transaction builds on Agilent's position as a leader in\npathology, well-positioning the Company to address evolving customer needs as\nthe market embraces digitalization and AI.\n\n * Enhances Companion Diagnostics and Biopharma Drug Discovery Offerings. By\nleveraging a growing repository of real-world data, Proscia offers additional\nAI-enabled synergies with Agilent's companion diagnostics (CDx) business,\nenhancing value to biopharma partners as well as clinical and translational\nresearch customers.\n\n * Supports Agilent's Long-Term Growth Profile. Proscia’s recurring-revenue\nmodel will add a high-growth, high-margin software business to Agilent's\npathology portfolio.\n\nThe transaction is subject to customary closing conditions and is expected to\nclose early in Agilent’s fiscal year 2027. Upon closing, Proscia will become\npart of the Agilent Life Sciences and Diagnostics Markets Group.\n\nAdvisers\n\nDLA Piper LLP (US) is serving as legal adviser and Joele Frank is serving as\nstrategic communications adviser to Agilent.\n\nCooley LLP is serving as legal adviser to Proscia.\n\nAbout Agilent Technologies\n\nAgilent Technologies, Inc. (NYSE: A) is a global leader in analytical and\nclinical laboratory technologies, delivering insights and innovation that help\nour customers bring great science to life. Agilent’s full range of solutions\nincludes instruments, software, services, and expertise that provide trusted\nanswers to our customers' most challenging questions. The company generated\nrevenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000\npeople worldwide. Information about Agilent is available at www.agilent.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.agilent.com%2F&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=www.agilent.com&index=1&md5=d7471f731758e2e9e763ab654acb8687)\n. To receive the latest Agilent news, subscribe to the Agilent Newsroom\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.agilent.com%2Fabout%2Fnewsroom%2Fsubscribe%2F&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=Agilent+Newsroom&index=2&md5=fd5181fa2430b1aea6aea3117c446949)\n. Follow Agilent on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2F1526%2F&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=LinkedIn&index=3&md5=2d74ac335a02c777b95c3888a724f5fb)\nand Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FAgilent.Tech&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=Facebook&index=4&md5=7be17892fc969c4ee77a365827cb0dbc)\n.\n\nAbout Proscia\n\nProscia is the pathology AI company rewiring pathology for precision medicine\nacross drug discovery, development, and diagnosis. Its Concentriq platform\nbrings intelligence to the scientists, pathologists, and laboratory leaders\nbehind the most critical decisions in medicine, helping more breakthroughs\nreach the patients they were made for. Proscia is trusted by 16 of the top 20\npharmaceutical companies and was named Global 2026 Best in KLAS for Digital\nPathology in Europe. Learn more at proscia.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fproscia.com%2F&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=proscia.com&index=5&md5=e640c00df2383a62287979b0a9ec5db5)\n, and follow Proscia on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fproscia%2Fhome%2F&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=LinkedIn&index=6&md5=465b360ec5649d6c9ff5a735dea43c08)\nand X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2Fproscia&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=X&index=7&md5=24280d17ddf9ed4bb551fd7875459d32)\n.\n\nForward Looking Statements\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains statements that constitute “forward-looking\nstatements” within the meaning of applicable U.S. securities laws. All\nstatements herein other than historical facts, including, without limitation,\nstatements regarding Agilent management’s current expectations, assumptions,\nestimates and projections regarding the industry in which Agilent operates,\ngeneral economic conditions, Agilent’s businesses and its financial\nperformance or condition, and future events, including the proposed\ntransaction with Proscia referred to in this press release, are\nforward-looking statements. Such forward-looking statements rely on the safe\nharbor provisions of Section 27A of the U.S. Securities Act of 1933, as\namended, and Section 21E of the U.S. Securities Exchange Act of 1934, as\namended. Because such forward-looking statements are subject to risks and\nuncertainties, actual results and future trends may differ materially from\nthose expressed in or implied by such forward-looking statements. Accordingly,\npotential investors and Agilent securityholders should not place undue\nreliance on such forward-looking statements. Words and phrases such as\n“anticipate,” “believe,” “combined company,” “could,”\n“consider,” “create,” “drive,” “expect,” “forecast,”\n“future,” “growth,” “hope,” “intend,” “opportunity,”\n“plan,” “potential,” “projected,” “proposal,” “result in,”\n“synergies,” “unlock,” “upside,” “will,” “would,” and\nsimilar words and phrases are intended to identify forward-looking statements.\nAmong the risks and uncertainties that could cause actual results to differ\nfrom those described in forward-looking statements are the following: the risk\nthat the transaction with Proscia may not be consummated; the risk that any\nconditions to the completion of the transaction with Proscia may not be\nsatisfied; risks relating to the future performance, results of operations,\nliquidity and financial position of each of Agilent, Proscia and the combined\ncompany resulting from the consummation of the transaction with Proscia; the\npossibility that the combined company following consummation of the\ntransaction with Proscia may not achieve expected synergies and operating\nefficiencies within the expected timeframes, or at all; the risk that\nconsummating the transaction with Proscia may be less accretive than expected,\nor may be dilutive, to Agilent’s earnings per share, which may negatively\naffect the market price of Agilent’s common stock; the risk that the\nintegration of Proscia’s operations with those of Agilent may be more\ndifficult, time-consuming and costly than expected, or that operating costs\nand business disruption may be greater than expected; the risk that any\nannouncements relating to, or the completion of, the transaction with Proscia\ncould have an adverse effect on the market price of Agilent’s common stock;\nthe risk that Agilent and Proscia may incur significant transaction and other\ncosts in connection with the transaction, and that those costs may exceed\nthose anticipated by Agilent; and risks related to any unforeseen liabilities\nof, and future capital expenditures required by, Agilent following\nconsummation of the transaction with Proscia.\n\nAdditional risks and uncertainties relating to forward-looking statements in\nrespect of Agilent’s businesses, operations, prospects and financial\nperformance and condition can be found in Agilent’s filings with the\nSecurities and Exchange Commission (the “SEC”), including the risks,\nuncertainties and other factors discussed in the sections entitled “Risk\nFactors” and “Forward-Looking Statements” in Agilent’s Annual Report\non Form 10-K for the fiscal year ended October 31, 2025, filed with the SEC on\nDecember 19, 2025, and the other filings Agilent has made or will make with\nthe SEC after such date, copies of which may be obtained from the SEC’s\nwebsite at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=www.sec.gov&index=8&md5=ef04eb9f1ec3d10ca78673b923707cf5)\n. All forward-looking statements contained herein and in the exhibits hereto\nare made only as of the date hereof, and Agilent disclaims any intention or\nobligation to update or revise any such forward-looking statements to reflect\nevents or circumstances that subsequently occur, or of which Agilent hereafter\nbecomes aware, except as required by applicable law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261013873030/en/\n(https://www.businesswire.com/news/home/20261013873030/en/)\n\nAgilent\n\nINVESTOR CONTACT \n\nTejas Savant\n\n+1 917-574-4018\n\ntejas.savant@agilent.com (mailto:tejas.savant@agilent.com)\n\nMEDIA CONTACT \n\nChristian Colón\n\n+1 302-867-4117\n\nchristian.colon@agilent.com (mailto:christian.colon@agilent.com)\n\nProscia\n\nMEDIA CONTACT \n\nSydney Fenkell\n\n+1 215-816-3436\n\nsydney@proscia.com (mailto:sydney@proscia.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw4KfFrDa-20261013","title":"Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence","author":"Business Wire","ticker":"A","created":"2026-10-13T12:00:00.446Z","tickers":["A"],"exchange":"NYSE","article_body":"Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and\nScientific Intelligence\n\nAdvances Agilent’s position as a leading pathology solutions provider, with\na unique and differentiated combination of instruments, reagents, and software\n\nAcquisition seamlessly builds on Agilent’s pathology portfolio expansion\nefforts and widens strategic moat in high-growth market\n\nAgilent Technologies Inc. (NYSE: A) today announced it has entered into a\ndefinitive agreement to acquire Proscia®, a provider of digital pathology\nsoftware for clinical and life-sciences customers, in an all-cash transaction\nvalued at $240 million in cash at closing and up to an additional $30 million\nbased on achieving future performance milestones.\n\nProscia is a leading independent provider of enterprise digital pathology\nsoftware, serving as a key enabler to address emerging trends in the $5\nbillion Pathology market. Proscia’s software platform serves as a central\noperating layer for digital pathology, supporting clinical and life-sciences\ncustomers across the U.S. and Europe. By connecting slide scanners, laboratory\ninformation systems, image-analysis applications, AI tools, people, and data,\nProscia’s innovative technology enables customers to manage images, data,\nand workflows in one unified environment. Proscia serves more than 4,000\nlaboratories, hospitals, and clinics today as well as 16 of the top 20\npharmaceutical companies, with trailing twelve months revenue exceeding $18\nmillion. Proscia was named 2026 Best in KLAS for Digital Pathology and earned\nthe highest performance score across both U.S. and European markets.\n\nAgilent and Proscia entered into a multi-year distribution agreement in\nSeptember 2022 to offer a comprehensive digital diagnostic-pathology system.\nToday’s announcement builds on Agilent’s established pathology solutions\nand its partnership with Proscia.\n\n“Digital pathology is quickly becoming the foundation for pathology data\ngeneration, analysis, and application across biopharmaceutical research,\nclinical development, and diagnostics, and our acquisition of Proscia\nmeaningfully expands our presence in this fast-growing market,” said Agilent\nPresident and CEO Padraig McDonnell. “The acquisition establishes an Agilent\nplatform for scientific intelligence in tissue-based precision medicine,\nconnecting data generation with AI-based interpretation in a workflow that\nsupports biomarker research through routine clinical use. With Proscia’s\nleading platform and talented team, we will be better equipped to help\nlaboratories and biopharma customers manage and derive insights from pathology\ndata. We look forward to welcoming the Proscia team to Agilent and working\ntogether to accelerate adoption of AI-enabled pathology workflows to advance\ndrug discovery and companion-diagnostics solutions and create long-term value\nfor customers and shareholders.”\n\n“This agreement with Agilent marks an exciting milestone for Proscia and\nreflects the strength of the platform our team has built,” said David West,\nCo-Founder and CEO of Proscia. “Agilent shares our vision for advancing\npathology through open, digital, and AI-enabled solutions. Together, we can\naccelerate innovation while continuing to provide customers with the\nflexibility they need across clinical and life-sciences workflows. I am\ngrateful to the entire Proscia team, whose dedication made this milestone\npossible, and look forward to building on our work as part of Agilent.”\n\nStrategic and Financial Benefits of the Acquisition\n\nThe combination builds on the successful completion of Agilent’s recent\ntransaction with Biocare Medical, and offers meaningful strategic and\nfinancial benefits, including:\n\n\n * Strengthens Pathology Portfolio with a Leading Digital Pathology Platform.\nThis acquisition strengthens Agilent's existing leadership in pathology\ninstrumentation and reagents, combining industry-leading diagnostic\ncapabilities with Proscia's vendor-agnostic digital pathology platform and\nestablished customer base. Proscia’s platform holds FDA 510(k) clearance for\nprimary diagnosis. The transaction builds on Agilent's position as a leader in\npathology, well-positioning the Company to address evolving customer needs as\nthe market embraces digitalization and AI.\n\n * Enhances Companion Diagnostics and Biopharma Drug Discovery Offerings. By\nleveraging a growing repository of real-world data, Proscia offers additional\nAI-enabled synergies with Agilent's companion diagnostics (CDx) business,\nenhancing value to biopharma partners as well as clinical and translational\nresearch customers.\n\n * Supports Agilent's Long-Term Growth Profile. Proscia’s recurring-revenue\nmodel will add a high-growth, high-margin software business to Agilent's\npathology portfolio.\n\nThe transaction is subject to customary closing conditions and is expected to\nclose early in Agilent’s fiscal year 2027. Upon closing, Proscia will become\npart of the Agilent Life Sciences and Diagnostics Markets Group.\n\nAdvisers\n\nDLA Piper LLP (US) is serving as legal adviser and Joele Frank is serving as\nstrategic communications adviser to Agilent.\n\nCooley LLP is serving as legal adviser to Proscia.\n\nAbout Agilent Technologies\n\nAgilent Technologies, Inc. (NYSE: A) is a global leader in analytical and\nclinical laboratory technologies, delivering insights and innovation that help\nour customers bring great science to life. Agilent’s full range of solutions\nincludes instruments, software, services, and expertise that provide trusted\nanswers to our customers' most challenging questions. The company generated\nrevenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000\npeople worldwide. Information about Agilent is available at www.agilent.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.agilent.com%2F&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=www.agilent.com&index=1&md5=d7471f731758e2e9e763ab654acb8687)\n. To receive the latest Agilent news, subscribe to the Agilent Newsroom\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.agilent.com%2Fabout%2Fnewsroom%2Fsubscribe%2F&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=Agilent+Newsroom&index=2&md5=fd5181fa2430b1aea6aea3117c446949)\n. Follow Agilent on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2F1526%2F&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=LinkedIn&index=3&md5=2d74ac335a02c777b95c3888a724f5fb)\nand Facebook\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FAgilent.Tech&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=Facebook&index=4&md5=7be17892fc969c4ee77a365827cb0dbc)\n.\n\nAbout Proscia\n\nProscia is the pathology AI company rewiring pathology for precision medicine\nacross drug discovery, development, and diagnosis. Its Concentriq platform\nbrings intelligence to the scientists, pathologists, and laboratory leaders\nbehind the most critical decisions in medicine, helping more breakthroughs\nreach the patients they were made for. Proscia is trusted by 16 of the top 20\npharmaceutical companies and was named Global 2026 Best in KLAS for Digital\nPathology in Europe. Learn more at proscia.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fproscia.com%2F&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=proscia.com&index=5&md5=e640c00df2383a62287979b0a9ec5db5)\n, and follow Proscia on LinkedIn\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fproscia%2Fhome%2F&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=LinkedIn&index=6&md5=465b360ec5649d6c9ff5a735dea43c08)\nand X\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2Fproscia&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=X&index=7&md5=24280d17ddf9ed4bb551fd7875459d32)\n.\n\nForward Looking Statements\n\nCautionary Note Regarding Forward-Looking Statements\n\nThis press release contains statements that constitute “forward-looking\nstatements” within the meaning of applicable U.S. securities laws. All\nstatements herein other than historical facts, including, without limitation,\nstatements regarding Agilent management’s current expectations, assumptions,\nestimates and projections regarding the industry in which Agilent operates,\ngeneral economic conditions, Agilent’s businesses and its financial\nperformance or condition, and future events, including the proposed\ntransaction with Proscia referred to in this press release, are\nforward-looking statements. Such forward-looking statements rely on the safe\nharbor provisions of Section 27A of the U.S. Securities Act of 1933, as\namended, and Section 21E of the U.S. Securities Exchange Act of 1934, as\namended. Because such forward-looking statements are subject to risks and\nuncertainties, actual results and future trends may differ materially from\nthose expressed in or implied by such forward-looking statements. Accordingly,\npotential investors and Agilent securityholders should not place undue\nreliance on such forward-looking statements. Words and phrases such as\n“anticipate,” “believe,” “combined company,” “could,”\n“consider,” “create,” “drive,” “expect,” “forecast,”\n“future,” “growth,” “hope,” “intend,” “opportunity,”\n“plan,” “potential,” “projected,” “proposal,” “result in,”\n“synergies,” “unlock,” “upside,” “will,” “would,” and\nsimilar words and phrases are intended to identify forward-looking statements.\nAmong the risks and uncertainties that could cause actual results to differ\nfrom those described in forward-looking statements are the following: the risk\nthat the transaction with Proscia may not be consummated; the risk that any\nconditions to the completion of the transaction with Proscia may not be\nsatisfied; risks relating to the future performance, results of operations,\nliquidity and financial position of each of Agilent, Proscia and the combined\ncompany resulting from the consummation of the transaction with Proscia; the\npossibility that the combined company following consummation of the\ntransaction with Proscia may not achieve expected synergies and operating\nefficiencies within the expected timeframes, or at all; the risk that\nconsummating the transaction with Proscia may be less accretive than expected,\nor may be dilutive, to Agilent’s earnings per share, which may negatively\naffect the market price of Agilent’s common stock; the risk that the\nintegration of Proscia’s operations with those of Agilent may be more\ndifficult, time-consuming and costly than expected, or that operating costs\nand business disruption may be greater than expected; the risk that any\nannouncements relating to, or the completion of, the transaction with Proscia\ncould have an adverse effect on the market price of Agilent’s common stock;\nthe risk that Agilent and Proscia may incur significant transaction and other\ncosts in connection with the transaction, and that those costs may exceed\nthose anticipated by Agilent; and risks related to any unforeseen liabilities\nof, and future capital expenditures required by, Agilent following\nconsummation of the transaction with Proscia.\n\nAdditional risks and uncertainties relating to forward-looking statements in\nrespect of Agilent’s businesses, operations, prospects and financial\nperformance and condition can be found in Agilent’s filings with the\nSecurities and Exchange Commission (the “SEC”), including the risks,\nuncertainties and other factors discussed in the sections entitled “Risk\nFactors” and “Forward-Looking Statements” in Agilent’s Annual Report\non Form 10-K for the fiscal year ended October 31, 2025, filed with the SEC on\nDecember 19, 2025, and the other filings Agilent has made or will make with\nthe SEC after such date, copies of which may be obtained from the SEC’s\nwebsite at www.sec.gov\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov&esheet=54620857&newsitemid=20261013873030&lan=en-US&anchor=www.sec.gov&index=8&md5=ef04eb9f1ec3d10ca78673b923707cf5)\n. All forward-looking statements contained herein and in the exhibits hereto\nare made only as of the date hereof, and Agilent disclaims any intention or\nobligation to update or revise any such forward-looking statements to reflect\nevents or circumstances that subsequently occur, or of which Agilent hereafter\nbecomes aware, except as required by applicable law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261013873030/en/\n(https://www.businesswire.com/news/home/20261013873030/en/)\n\nAgilent\n\nINVESTOR CONTACT \n\nTejas Savant\n\n+1 917-574-4018\n\ntejas.savant@agilent.com (mailto:tejas.savant@agilent.com)\n\nMEDIA CONTACT \n\nChristian Colón\n\n+1 302-867-4117\n\nchristian.colon@agilent.com (mailto:christian.colon@agilent.com)\n\nProscia\n\nMEDIA CONTACT \n\nSydney Fenkell\n\n+1 215-816-3436\n\nsydney@proscia.com (mailto:sydney@proscia.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-13T12:00:00.706565101Z","server_sent_at_ms":1791892800706},"received_at":"2026-10-13T12:00:00.758Z","source_url":"https://www.businesswire.com/news/home/20261013873030/en/"},"analysis":{"id":"155717","press_release_id":"167413","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["Deal carries up to $30M contingent milestone payments","Risk factors note deal may be dilutive to EPS and integration costs may exceed expectations"],"eventType":"m_and_a","narrative":"Agilent Technologies agreed to acquire digital pathology software provider Proscia in an all-cash deal valued at $240 million at closing, plus up to $30 million in performance-milestone payments.\n\nProscia serves more than 4,000 laboratories, hospitals, and clinics and 16 of the top 20 pharmaceutical companies, with trailing twelve-month revenue exceeding $18 million and FDA 510(k) clearance for primary diagnosis.\n\nThe acquisition adds a high-growth, recurring-revenue software layer to Agilent's pathology portfolio and is expected to close early in Agilent's fiscal year 2027, subject to customary conditions.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Agilent deepens its AI/digital pathology moat with a bolt-on software acquisition in the $5B pathology market."},"keyFigures":{"dealValueUsd":240000000,"customDimensions":{"target_customers":"4,000+ labs/hospitals/clinics; 16 of top 20 pharma companies","earnout_potential":"$30 million","addressable_market":"$5 billion pathology market","target_ttm_revenue":"$18 million","agilent_fy25_revenue":"$6.95 billion"}},"quotedText":"Digital pathology is quickly becoming the foundation for pathology data generation, analysis, and application across biopharmaceutical research, clinical development, and diagnostics, and our acquisition of Proscia meaningfully expands our presence in this fast-growing market","namedEntities":{"people":[{"name":"Padraig McDonnell","role":"President and CEO of Agilent"},{"name":"David West","role":"Co-Founder and CEO of Proscia"},{"name":"Tejas Savant","role":"Investor contact, Agilent"},{"name":"Christian Colón","role":"Media contact, Agilent"},{"name":"Sydney Fenkell","role":"Media contact, Proscia"}],"products":["Concentriq"],"companies":[{"name":"Agilent Technologies Inc.","ticker":"A","relationship":"acquirer"},{"name":"Proscia","relationship":"target"},{"name":"Biocare Medical","relationship":"prior acquisition target"},{"name":"DLA Piper LLP (US)","relationship":"legal adviser to Agilent"},{"name":"Joele Frank","relationship":"communications adviser to Agilent"},{"name":"Cooley LLP","relationship":"legal adviser to Proscia"}],"dollarAmounts":[{"amount":"$240 million","context":"all-cash consideration at closing"},{"amount":"$30 million","context":"potential milestone-based earnout payments"},{"amount":"$18 million","context":"Proscia trailing twelve months revenue"},{"amount":"$5 billion","context":"pathology market size"},{"amount":"$6.95 billion","context":"Agilent fiscal year 2025 revenue"}]},"materialImpact":{"score":3,"reasoning":"Agilent announced a definitive agreement to acquire Proscia for $240M cash plus up to $30M in earnout milestones. The deal is strategically meaningful (digital pathology, AI, recurring-revenue software) but small relative to Agilent's $6.95B fiscal 2025 revenue, so not market-moving."},"tickerRelevance":{"others":[],"primary":"A"},"globalImportance":42,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap S&P 500","eventGravity":"bolt-on M&A ~$240M","sectorWeight":"health care / life sciences tools","dealSizeRelativeToAcquirer":"small (~3.5% of FY25 revenue)"}},"event_type":"m_and_a","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Agilent Technologies agreed to acquire digital pathology software provider Proscia in an all-cash deal valued at $240 million at closing, plus up to $30 million in performance-milestone payments.\n\nProscia serves more than 4,000 laboratories, hospitals, and clinics and 16 of the top 20 pharmaceutical companies, with trailing twelve-month revenue exceeding $18 million and FDA 510(k) clearance for primary diagnosis.\n\nThe acquisition adds a high-growth, recurring-revenue software layer to Agilent's pathology portfolio and is expected to close early in Agilent's fiscal year 2027, subject to customary conditions.","key_figures":{"dealValueUsd":240000000,"customDimensions":{"target_customers":"4,000+ labs/hospitals/clinics; 16 of top 20 pharma companies","earnout_potential":"$30 million","addressable_market":"$5 billion pathology market","target_ttm_revenue":"$18 million","agilent_fy25_revenue":"$6.95 billion"}},"named_entities":{"people":[{"name":"Padraig McDonnell","role":"President and CEO of Agilent"},{"name":"David West","role":"Co-Founder and CEO of Proscia"},{"name":"Tejas Savant","role":"Investor contact, Agilent"},{"name":"Christian Colón","role":"Media contact, Agilent"},{"name":"Sydney Fenkell","role":"Media contact, Proscia"}],"products":["Concentriq"],"companies":[{"name":"Agilent Technologies Inc.","ticker":"A","relationship":"acquirer"},{"name":"Proscia","relationship":"target"},{"name":"Biocare Medical","relationship":"prior acquisition target"},{"name":"DLA Piper LLP (US)","relationship":"legal adviser to Agilent"},{"name":"Joele Frank","relationship":"communications adviser to Agilent"},{"name":"Cooley LLP","relationship":"legal adviser to Proscia"}],"dollarAmounts":[{"amount":"$240 million","context":"all-cash consideration at closing"},{"amount":"$30 million","context":"potential milestone-based earnout payments"},{"amount":"$18 million","context":"Proscia trailing twelve months revenue"},{"amount":"$5 billion","context":"pathology market size"},{"amount":"$6.95 billion","context":"Agilent fiscal year 2025 revenue"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-13T12:00:08.019Z","global_importance":42,"audience_relevance":35,"importance_components":{"tickerTier":"large-cap S&P 500","eventGravity":"bolt-on M&A ~$240M","sectorWeight":"health care / life sciences tools","dealSizeRelativeToAcquirer":"small (~3.5% of FY25 revenue)"}},"durationMs":7227,"modelName":"glm-5.3-flashx"}}